TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has issued an update.
On November 18, 2025, OKYO Pharma Limited announced that its CEO, Gary S. Jacob, will present at the Ophthalmology Innovation Summit (OIS) XV in San Diego, scheduled for November 22, 2025. The presentation will focus on urcosimod, OKYO’s lead investigational drug for treating neuropathic corneal pain (NCP), a condition with no FDA-approved therapies. The announcement highlights OKYO’s recent positive Phase 2 trial results and its plans for a larger clinical trial, underscoring the company’s commitment to addressing unmet medical needs in the ophthalmic field.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.
OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is engaged in the discovery and development of novel molecules to treat ocular diseases and has its ordinary shares listed on the NASDAQ Capital Market.
Average Trading Volume: 122,849
Technical Sentiment Signal: Buy
Current Market Cap: $84.4M
For a thorough assessment of OKYO stock, go to TipRanks’ Stock Analysis page.